BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Gubra readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Gubra's drugs run\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07662122-153@assetmemo.bio
DTSTAMP:20261121T005448Z
DTSTART;VALUE=DATE:20270626
DTEND;VALUE=DATE:20270627
SUMMARY:BI 3034701: Phase 2 readout est. (NCT07662122)
DESCRIPTION:BI 3034701\, phase 2\, Obesity.\nStudy: A Study to Test Whether
  BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweigh
 t\nEstimated primary completion: 26 June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/bi-3034701#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07662122
URL:https://assetmemo.bio/drug/bi-3034701#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07702890-170@assetmemo.bio
DTSTAMP:20261121T005448Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:GUB-UCN2: Phase 1/2 readout est. (NCT07702890)
DESCRIPTION:GUB-UCN2\, phase 1/2\, Obesity.\nStudy: A Three-part First-in-h
 uman Trial to Assess Safety\, Tolerability\, Pharmacokinetics and Pharmaco
 dynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participan
 ts With T2D\nEstimated primary completion: December 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/gub-ucn2#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07702890
URL:https://assetmemo.bio/drug/gub-ucn2#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
